【摘要】 目的:探討單次注射輕比重單側(cè)腰麻與全麻用于老年髖關(guān)節(jié)置換合并慢性阻塞性肺疾病(COPD)患者的價(jià)值。方法:選擇2019年1月—2022年1月漳州正興醫(yī)院收治的80例行老年髖關(guān)節(jié)置換術(shù)合并COPD患者為研究對(duì)象,隨機(jī)分為單側(cè)腰麻組和全麻組,各40例。比較兩組手術(shù)情況(阻滯起效時(shí)間、完全阻滯時(shí)間、手術(shù)時(shí)間)、各時(shí)間點(diǎn)血流動(dòng)力學(xué)指標(biāo)[心率(HR)、平均動(dòng)脈壓(MAP)及血氧飽和度(SpO2)]、各時(shí)間點(diǎn)空腹血糖及血清皮質(zhì)醇(CORT)及兒茶酚胺(CA)水平、手術(shù)前后蒙特利爾認(rèn)知評(píng)估量表(MoCA)及簡易智力量表(MMSE)及視覺模擬評(píng)分法(VAS)評(píng)分,比較兩組不良反應(yīng)發(fā)生率。結(jié)果:單側(cè)腰麻組阻滯起效時(shí)間、完全阻滯時(shí)間、手術(shù)時(shí)間均短于全麻組(Plt;0.05);兩組各時(shí)間點(diǎn)血流動(dòng)力學(xué)指標(biāo)比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05),兩組手術(shù)結(jié)束時(shí)MAP、HR均低于手術(shù)前與術(shù)后24 h(Plt;0.05),且兩組手術(shù)前與術(shù)后24 h的MAP、HR比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05);手術(shù)結(jié)束時(shí),兩組空腹血糖、CORT、CA均高于手術(shù)前與術(shù)后24 h(Plt;0.05),且單側(cè)腰麻組空腹血糖、CORT、CA水平均低于全麻組(Plt;0.05);手術(shù)后兩組MoCA、MMSE及VAS評(píng)分均低于手術(shù)前(Plt;0.05),單側(cè)腰麻組MoCA、MMSE評(píng)分均高于全麻組(Plt;0.05),兩組VAS評(píng)分比較,差異無統(tǒng)計(jì)學(xué)意義(Pgt;0.05);單側(cè)腰麻組不良反應(yīng)發(fā)生率低于全麻組(Plt;0.05)。結(jié)論:兩種麻醉方式均對(duì)髖關(guān)節(jié)置換合并COPD患者有效,但單次注射輕比重單側(cè)腰麻更適用于老年患者,可有效穩(wěn)定血流動(dòng)力學(xué),調(diào)節(jié)應(yīng)激反應(yīng)指標(biāo),抑制應(yīng)激反應(yīng),且具有較高的安全性。
【關(guān)鍵詞】 單側(cè)腰麻 全身麻醉 老年髖關(guān)節(jié)置換術(shù) 慢性阻塞性肺疾病
Value of Single Injection with Light Weight Unilateral Lumbar Anesthesia and General Anesthesia in Elderly Patients with Hip Replacement Complicated with COPD/SONG Wei. //Medical Innovation of China, 2025, 22(03): -112
[Abstract] Objective: To investigate the value of single injection of light weight unilateral lumbar anesthesia and general anesthesia in elderly patients with hip replacement complicated with chronic obstructive pulmonary disease (COPD). Method: A total of 80 elderly patients with COPD who underwent hip replacement in Zhangzhou Zhengxing Hospital from January 2019 to January 2022 were selected as the research objects, and they were randomly divided into unilateral lumbar anesthesia group and general anesthesia group, with 40 cases in each group. The surgical conditions (time of onset of block effect, time of complete block, and time of surgery), hemodynamic indexes [heart rate (HR), mean arterial pressure (MAP), and oxygen saturation (SpO2)] at each time point, fasting blood glucose and serum cortisol (CORT) and catecholamine (CA) levels at each time point, the scores of Montreal cognitive assessment (MoCA), mini-mental state examination (MMSE) and visual analogue scale (VAS) before and after surgery were compared between the two groups, and the incidence of adverse reactions was compared between the two groups. Result: The time of block onset, time of complete block and time of surgery in unilateral lumbar anesthesia group were shorter than those in general anesthesia group (Plt;0.05). There were no statistically significant differences in the hemodynamic indexes at each time point between the two groups (Pgt;0.05). MAP and HR in both groups at the end of surgery were lower than those before surgery and 24 h after surgery (Plt;0.05), and there were no statistically significant differences in MAP and HR of the two groups before surgery and 24 h after surgery (Pgt;0.05). At the end of surgery, fasting blood glucose, CORT and CA in both groups were higher than those before surgery and 24 h after surgery (Plt;0.05), and the levels of fasting blood glucose, CORT and CA in unilateral lumbar anesthesia group were lower than those in general anesthesia group (Plt;0.05). After surgery, MoCA, MMSE and VAS scores of the two groups were lower than those before surgery (Plt;0.05), MoCA and MMSE scores of the unilateral lumbar anesthesia group were higher than those of the general anesthesia group (Plt;0.05), and there was no statistically significant difference in VAS score between the two groups (Pgt;0.05). The incidence of adverse reactions in unilateral lumbar anesthesia group was lower than that in general anesthesia group (Plt;0.05). Conclusion: Both anesthesia methods are effective for patients with hip replacement combined with COPD, but single injection of light weight unilateral lumbar anesthesia is more suitable for elderly patients. It can effectively stabilize hemodynamics, regulate stress response indicators, inhibit stress response, and has high safety.
[Key words] Unilateral spinal anesthesia General anesthesia Elderly hip replacement surgery Chronic obstructive pulmonary disease
First-author's address: Department of Anesthesiology, Zhangzhou Zhengxing Hospital, Zhangzhou 363000, China
doi:10.3969/j.issn.1674-4985.2025.03.025
股骨頸骨折與股骨頭壞死為老年群體常見疾病,主要治療方法為髖關(guān)節(jié)置換術(shù),隨著人口老齡化加劇,行髖關(guān)節(jié)置換術(shù)的老年患者逐漸增多,又因老年患者機(jī)體不斷退化,多伴有呼吸系統(tǒng)、心血管系統(tǒng)的基礎(chǔ)疾病[1]。慢性阻塞性肺疾病(COPD)為常見老年患者術(shù)前合并癥之一,術(shù)前即存在氣道阻塞、呼吸不暢等癥狀,致使患者對(duì)手術(shù)麻醉的耐受力變低,從而導(dǎo)致血流動(dòng)力學(xué)紊亂,出現(xiàn)不同程度應(yīng)激反應(yīng)[2]。因此術(shù)前對(duì)患者COPD病情進(jìn)行詳細(xì)評(píng)估,減少術(shù)后并發(fā)癥的發(fā)生率,選擇合適的麻醉藥物及方式是臨床需解決的首要問題[3]。目前臨床常用麻醉方式為單側(cè)腰部麻醉與全身麻醉,兩者在下肢手術(shù)中均以得到廣泛應(yīng)用,但在老年髖關(guān)節(jié)置換術(shù)中選擇何種方式仍存較大爭(zhēng)議,有研究指出單側(cè)腰部麻醉術(shù)后死亡率較低,亦有學(xué)者證實(shí)全身麻醉術(shù)后患者應(yīng)激反應(yīng)較小,但均未提及麻醉方式對(duì)合并COPD患者的影響[4-5]。基于此本研究將探討單次注射輕比重單側(cè)腰麻與全麻用于老年髖關(guān)節(jié)置換合并COPD患者的價(jià)值,為臨床選擇麻醉方式提供參考依據(jù)。
1 資料與方法
1.1 一般資料
選擇2019年1月—2022年1月漳州正興醫(yī)院收治的80例行老年髖關(guān)節(jié)置換術(shù)合并COPD患者為研究對(duì)象。納入標(biāo)準(zhǔn):(1)COPD分級(jí)與診斷標(biāo)準(zhǔn)參照文獻(xiàn)[6]《慢性阻塞性肺疾病基層診療指南(實(shí)踐版·2018)》;(2)符合髖關(guān)節(jié)置換術(shù)指征;(3)髖關(guān)節(jié)解剖無異常。排除標(biāo)準(zhǔn):(1)既往髖關(guān)節(jié)手術(shù)史;(2)合并心、肝、腎等臟器功能衰竭;(3)合并其他免疫系統(tǒng)疾??;(4)認(rèn)知功能障礙。隨機(jī)分為單側(cè)腰麻組和全麻組,各40例?;颊呒捌浼覍賹?duì)本次研究知情同意并簽署知情同意書。本研究經(jīng)漳州正興醫(yī)院醫(yī)學(xué)倫理委員會(huì)批準(zhǔn)(2019-010)。
1.2 方法
所有患者術(shù)前常規(guī)禁食禁飲,術(shù)前30 min給予0.1 g苯巴比妥鈉(生產(chǎn)廠家:遂成藥業(yè)股份有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H41025613,規(guī)格1 mL︰0.1 g)經(jīng)肌肉注射,入手術(shù)室后常規(guī)消毒、鋪巾連接監(jiān)護(hù)儀監(jiān)測(cè)并記錄各項(xiàng)生命體征。面罩吸入氧濃度3 L/min。建立靜脈通道后輸入300~500 mL乳酸林格液(生產(chǎn)廠家:上海華源安徽錦輝制藥有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H34023288,規(guī)格:250 mL)。單側(cè)腰麻組患者保持患側(cè)朝上的側(cè)臥位,椎間隙行硬膜外穿刺選L2~3或L3~4位,成功后開口朝向手術(shù)側(cè)插入腰穿針,單次注射輕比重0.5%布比卡因(生產(chǎn)廠家:山東華魯制藥有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H37022106,規(guī)格:5 mL︰25 mg)6 mg,注射速率為0.1 mL/s,向頭端置入3 cm硬膜外導(dǎo)管。測(cè)定腰麻阻滯范圍則采用針刺法,需及時(shí)調(diào)整頭位高低使之達(dá)到平面T10~12,術(shù)中密切關(guān)注麻醉效果及時(shí)追加麻藥。全麻組采用0.03 mg/kg咪達(dá)唑侖(生產(chǎn)廠家:江蘇恩華藥業(yè)集團(tuán)有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H20031071,規(guī)格:5 mL︰5 mg)、0.2~0.3 mg/kg依托咪酯(生產(chǎn)廠家:江蘇恩華藥業(yè)集團(tuán)有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H32022992,規(guī)格:10 mL︰20 mg)、0.5~1 μg/kg舒芬太尼(生產(chǎn)廠家:宜昌人福藥業(yè)有限責(zé)任公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H20054171,規(guī)格:1 mL︰50 μg)、0.8~1.0 mg羅庫溴銨(生產(chǎn)廠家:浙江仙琚制藥股份有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H20093186,規(guī)格:5 mL︰50 mg)進(jìn)行靜脈麻醉誘導(dǎo),待肌肉松弛后進(jìn)行氣管插管,連接麻醉機(jī)行機(jī)械通氣,呼吸頻率(RR)、潮氣量(VT)、吸呼比(I︰E)分別調(diào)整至12~15次/min、8~10 mL/kg及1︰2。吸入氧濃度1~2 L/min、1%~2%異氟烷(生產(chǎn)廠家:魯南貝特制藥有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H20020267,規(guī)格:100 mL),每小時(shí)持續(xù)泵注3~5 mg/kg丙泊酚(生產(chǎn)廠家:四川國瑞藥業(yè)有限責(zé)任公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H20030115,規(guī)格:20 mL︰0.2 g)及0.1~0.2 μg/kg瑞芬太尼(生產(chǎn)廠家:江蘇恩華藥業(yè)集團(tuán)有限公司,批準(zhǔn)文號(hào):國藥準(zhǔn)字H20143314,規(guī)格:1 mg)進(jìn)行術(shù)中維持,采用間斷靜脈注射維庫溴銨維持肌肉松弛,監(jiān)測(cè)麻醉深度,將腦電雙頻譜指數(shù)控制在40~60,同上采用針刺法測(cè)定腰麻阻滯范圍并調(diào)整平面。
1.3 觀察指標(biāo)與判定標(biāo)準(zhǔn)
(1)比較兩組患者手術(shù)情況,記錄患者阻滯起效時(shí)間、完全阻滯時(shí)間、手術(shù)時(shí)間。(2)比較兩組患者各時(shí)間點(diǎn)血流動(dòng)力學(xué)指標(biāo),分別于手術(shù)前、手術(shù)結(jié)束時(shí)及術(shù)后24 h采用監(jiān)護(hù)儀(南京貝登醫(yī)療股份有限公司,uMEC7)觀察并記錄兩組患者的心率(HR)、平均動(dòng)脈壓(MAP)及血氧飽和度(SpO2)。(3)比較兩組患者各時(shí)間點(diǎn)空腹血糖、血清皮質(zhì)醇(CORT)、兒茶酚胺(CA)水平,采用血糖儀檢測(cè)空腹血糖,采用酶聯(lián)免疫吸附法檢測(cè)CORT、CA,試劑盒來自北京沃萊士生物科技有限公司,嚴(yán)格按照試劑盒說明書進(jìn)行操作。(4)比較兩組患者手術(shù)前后蒙特利爾認(rèn)知評(píng)估量表(MoCA)、簡易智力量表(MMSE)及視覺模擬評(píng)分法(VAS)評(píng)分,MoCA:注意與集中、執(zhí)行功能、記憶、語言、視結(jié)構(gòu)技能、抽象思維、計(jì)算和定向力等8個(gè)認(rèn)知領(lǐng)域,總分30分,≥26分為正常;MMSE:時(shí)間定向力,地點(diǎn)定向力,即刻記憶,注意力及計(jì)算力,延遲記憶,語言,視空間,總分30分,≥27分為正常;VAS:0~10分,分?jǐn)?shù)越高疼痛指數(shù)越高。(5)比較兩組患者惡心嘔吐、頭暈、呼吸困難等不良反應(yīng)發(fā)生率。
1.4 統(tǒng)計(jì)學(xué)處理
選用SPSS 22.0軟件對(duì)數(shù)據(jù)進(jìn)行統(tǒng)計(jì)學(xué)分析,計(jì)量資料以(x±s)表示,組間比較行獨(dú)立樣本t檢驗(yàn),組內(nèi)比較行配對(duì)t檢驗(yàn);計(jì)數(shù)資料以率(%)表示,組間比較行字2檢驗(yàn)。Plt;0.05為差異有統(tǒng)計(jì)學(xué)意義。
2 結(jié)果
2.1 兩組基線資料比較
單側(cè)腰麻組中男24例,女16例;年齡63~81歲,平均(72.36±5.14)歲;體重指數(shù)(BMI):21~26 kg/m2,平均(23.46±1.57)kg/m2;COPD分級(jí):1級(jí)13例,2級(jí)19例,3級(jí)8例;合并癥:糖尿病13例,高血壓15例,冠心病7例。全麻組中男26例,女14例;年齡60~82歲,平均(71.96±5.38)歲;BMI:21~27 kg/m2,平均(23.35±1.64)kg/m2;COPD分級(jí):1級(jí)15例,2級(jí)20例,3級(jí)5例;合并癥:糖尿病14例,高血壓17例,冠心病9例。兩組基線資料比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05),具有可比性。
2.2 兩組手術(shù)情況比較
單側(cè)腰麻組阻滯起效時(shí)間、完全阻滯時(shí)間、手術(shù)時(shí)間均短于全麻組(Plt;0.05),見表1。
2.3 兩組各時(shí)間點(diǎn)血流動(dòng)力學(xué)指標(biāo)比較
兩組各時(shí)間點(diǎn)血流動(dòng)力學(xué)指標(biāo)比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05);兩組手術(shù)結(jié)束時(shí)MAP、HR與手術(shù)前與術(shù)后24 h比較均更低(Plt;0.05),且兩組手術(shù)前與術(shù)后24 h的MAP、HR比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05)。見表2。
2.4 兩組各時(shí)間點(diǎn)空腹血糖、CORT、CA水平比較
手術(shù)前與術(shù)后24 h兩組空腹血糖、CORT、CA水平比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05);手術(shù)結(jié)束時(shí),兩組空腹血糖、CORT、CA均高于手術(shù)前與術(shù)后24 h(Plt;0.05),且單側(cè)腰麻組空腹血糖、CORT、CA水平均低于全麻組(Plt;0.05)。見表3。
2.5 兩組手術(shù)前后MoCA、MMSE及VAS評(píng)分比較
手術(shù)前兩組MoCA、MMSE及VAS評(píng)分比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05);手術(shù)后兩組MoCA、MMSE及VAS評(píng)分均低于手術(shù)前(Plt;0.05),單側(cè)腰麻組MoCA、MMSE評(píng)分均高于全麻組(Plt;0.05),兩組VAS評(píng)分比較,差異無統(tǒng)計(jì)學(xué)意義(Pgt;0.05)。見表4。
2.6 兩組不良反應(yīng)發(fā)生率比較
單側(cè)腰麻組不良反應(yīng)發(fā)生率低于全麻組(字2=4.501,P=0.033),見表5。
3 討論
髖關(guān)節(jié)置換術(shù)為緩解關(guān)節(jié)疼痛、矯正肢體畸形、改善關(guān)節(jié)運(yùn)動(dòng)功能的主要治療手段,隨著手術(shù)入路、切口長度變化,術(shù)中將涉及多處神經(jīng)血管,為一種有創(chuàng)大型手術(shù)[7]。髖關(guān)節(jié)病變的發(fā)生率隨著年齡增加而增加,而老年患者自身身體素質(zhì)較為低下,調(diào)節(jié)能力有所下降,且耐受力差,術(shù)后愈合能力緩慢,以上因素均將對(duì)患者預(yù)后產(chǎn)生影響[8]。COPD為老年患者常見全身性疾病之一,因其伴有全身炎癥反應(yīng),機(jī)體中含有大量炎癥細(xì)胞,而炎癥細(xì)胞將破壞成骨細(xì)胞,增加骨吸收量,骨形成減少,導(dǎo)致骨量失衡,進(jìn)一步誘發(fā)骨質(zhì)疏松[9]。據(jù)統(tǒng)計(jì)顯示,近60%的COPD患者伴有骨質(zhì)疏松,這一結(jié)果導(dǎo)致COPD患者需行髖關(guān)節(jié)置換術(shù)比例增加,同時(shí)因該類患者的特殊性,其機(jī)體防御力更為低下,肺功能差,肺循環(huán)阻力增加,手術(shù)風(fēng)險(xiǎn)更高,麻醉方式如何選擇顯得更為重要[10]。故本研究比較單次注射輕比重單側(cè)腰麻與全麻用于老年髖關(guān)節(jié)置換合并COPD患者的價(jià)值,為臨床提供參考依據(jù)。
本研究結(jié)果顯示,單側(cè)腰麻組阻滯起效時(shí)間、完全阻滯時(shí)間、手術(shù)時(shí)間均短于全麻組(Plt;0.05),兩組各時(shí)間點(diǎn)血流動(dòng)力學(xué)指標(biāo)比較,差異均無統(tǒng)計(jì)學(xué)意義(Pgt;0.05);手術(shù)結(jié)束時(shí)兩組MAP、HR與手術(shù)前與術(shù)后24 h比較均更低(Plt;0.05),提示單次注射輕比重單側(cè)腰麻對(duì)患者心血管循環(huán)系統(tǒng)影響小,且手術(shù)各項(xiàng)情況更佳。輕比重單側(cè)腰麻用于手術(shù)麻醉時(shí)劑量較小,可直接降低麻醉藥物對(duì)患者心血管造成的不良反應(yīng),更適用于老年患者[11]。經(jīng)研究證實(shí),單側(cè)腰麻在抑制下肢交感神經(jīng)方面作用優(yōu)于全麻,且麻醉效果僅作用于患側(cè),對(duì)健康一側(cè)的神經(jīng)阻滯作用較弱,相應(yīng)的血流動(dòng)力學(xué)的影響較小,更利于穩(wěn)定術(shù)中患者各項(xiàng)生命體征與促進(jìn)術(shù)后恢復(fù)[12]。但此麻醉方式易使患者不滿意麻醉效果,或出現(xiàn)雙側(cè)麻醉,故對(duì)麻醉醫(yī)師的操作技術(shù)要求更加嚴(yán)格,術(shù)中需密切關(guān)注患者情況,及時(shí)追加局麻藥物[13]。
手術(shù)創(chuàng)傷刺激引起交感-腎上腺髓質(zhì)及丘腦-垂體-腎上腺皮質(zhì)軸兩個(gè)系統(tǒng)興奮,從而進(jìn)行神經(jīng)分泌活動(dòng),引發(fā)應(yīng)激反應(yīng),已經(jīng)研究證實(shí),適當(dāng)?shù)膽?yīng)激反應(yīng)將保護(hù)機(jī)體,但應(yīng)激反應(yīng)過度則會(huì)損傷各項(xiàng)器官[14]。其中腎上腺皮質(zhì)分泌的CORT是反映應(yīng)激反應(yīng)的主要糖皮質(zhì)激素,通過調(diào)節(jié)腎上皮質(zhì)軸,維持身體的非特異性防御反應(yīng);另一個(gè)交感-腎上腺髓質(zhì)系統(tǒng)興奮時(shí)將釋放大量CA,與血流動(dòng)力學(xué)變化密切相關(guān),用于調(diào)節(jié)心血管功能[15-16]。血糖水平同樣是反映機(jī)體應(yīng)激反應(yīng)的一大重要指標(biāo),應(yīng)激反應(yīng)將減少機(jī)體分泌胰島素之類的合成激素,反而使胰高血糖素類的分解激素分泌增加,導(dǎo)致機(jī)體處于高代謝狀態(tài),甚至引發(fā)應(yīng)激性高血糖癥[17-18]。本研究結(jié)果顯示手術(shù)結(jié)束時(shí)兩組空腹血糖、CORT、CA平均高于手術(shù)前與術(shù)后24 h,且手術(shù)結(jié)束時(shí)單側(cè)腰麻組空腹血糖、CORT、CA水平均低于全麻組,提示手術(shù)創(chuàng)傷導(dǎo)致應(yīng)激反應(yīng)各項(xiàng)指標(biāo)上升,但單次注射輕比重單側(cè)腰麻的應(yīng)激反應(yīng)更小,更利于患者預(yù)后。
另比較兩組患者認(rèn)知功能以及疼痛程度發(fā)現(xiàn),手術(shù)后兩組MoCA、MMSE及VAS評(píng)分均低于手術(shù)前,但單側(cè)腰麻組MoCA、MMSE評(píng)分高于全麻組,兩組VAS評(píng)分無明顯差異,表明兩種麻醉方式均可有效緩解患者術(shù)后疼痛程度,但單側(cè)腰麻對(duì)患者認(rèn)知功能影響較小。分析是因腰麻僅作用于患側(cè),對(duì)中樞神經(jīng)系統(tǒng)影響較小,但全麻將直接影響中樞神經(jīng)系統(tǒng),導(dǎo)致認(rèn)識(shí)功能受到損害的風(fēng)險(xiǎn)增加[19-20]。最后分析兩組患者不良反應(yīng)發(fā)生率,結(jié)果顯示單側(cè)腰麻組不良反應(yīng)發(fā)生率顯著低于全麻組,表明單次注射輕比重單側(cè)腰麻安全性更好,更利于患者恢復(fù),與王冬梅等[21]研究結(jié)果相互印證。
綜上所述,兩種麻醉方式均對(duì)髖關(guān)節(jié)置換合并COPD患者有效,但單次注射輕比重單側(cè)腰麻更適用于老年患者,可有效穩(wěn)定血流動(dòng)力學(xué),調(diào)節(jié)應(yīng)激反應(yīng)指標(biāo),抑制應(yīng)激反應(yīng),且具有較高安全性。
參考文獻(xiàn)
[1] SONG J D,ZHANG G S,LIANG J L,et al.Effects of delayed hip replacement on postoperative hip function and quality of life in elderly patients with femoral neck fracture[J].BMC Musculoskelet Disord,2020,21(1):487.
[2] CARAMORI G,RUGGERI P,ARPINELLI F,et al.Long-term use of inhaled glucocorticoids in patients with stable chronic obstructive pulmonary disease and risk of bone fractures:a narrative review of the literature[J].Int J Chron Obstruct Pulmon Dis,2019,14:1085-1097.
[3]潘昌斌,陳靜.不同劑量右美托咪定復(fù)合瑞芬太尼在老年髖關(guān)節(jié)置換術(shù)麻醉中應(yīng)用[J].中國老年學(xué)雜志,2020,40(19):4129-4132.
[4]王勇軍.全身麻醉與腰硬聯(lián)合麻醉對(duì)老年髖關(guān)節(jié)置換患者術(shù)后疼痛和認(rèn)知功能的影響[J].中國全科醫(yī)學(xué),2019,22(S2):110-112.
[5] URVOY B,AVELINE C,BELOT N,et al.Opioid-free anaesthesia for anterior total hip replacement under general anaesthesia:the observational prospective study of opiate-free anesthesia for anterior total hip replacement trial[J].Br J Anaesth,2021,126(4):136-139.
[6]中華醫(yī)學(xué)會(huì),中華醫(yī)學(xué)會(huì)雜志社,中華醫(yī)學(xué)會(huì)全科醫(yī)學(xué)分會(huì),等.慢性阻塞性肺疾病基層診療指南(實(shí)踐版·2018)[J].中華全科醫(yī)師雜志,2018,17(11):871-877.
[7]李帥,朱衛(wèi),歐陽正曉,等.股骨頭重度壞死患者髖關(guān)節(jié)置換術(shù)中軟組織松解及髖臼重建術(shù)的應(yīng)用[J].中南大學(xué)學(xué)報(bào)(醫(yī)學(xué)版),2019,44(7):790-794.
[8]張真真,周曉艷,曹林,等.術(shù)前衰弱對(duì)行膝髖關(guān)節(jié)置換手術(shù)老年患者術(shù)后譫妄的影響[J].醫(yī)學(xué)研究生學(xué)報(bào),2021,34(4):371-374.
[9] BITAR A N,KHAN A H,SULAIMAN S,et al.Prevalence,risk assessment,and predictors of osteoporosis among chronic obstructive pulmonary disease patients[J].J Adv Pharm Technol Res,2021,12(4):395-401.
[10] TSUKAMOTO M,MORI T,NAKAMURA E,et al.Chronic obstructive pulmonary disease severity in middle-aged and older men with osteoporosis associates with decreased bone formation[J].Osteoporos Sarcopenia,2020,6(4):179-184.
[11]姜攀.羅哌卡因復(fù)合氫嗎啡酮單側(cè)腰麻在老年下肢手術(shù)中的應(yīng)用及羅哌卡因最低有效劑量研究[J].中國全科醫(yī)學(xué),2021,24(S02):132-134.
[12] ALPASLAN A,SEMA A B,SACIT G M.Effect of regional or general anesthesia methods on mortality according to age groups in geriatric hip surgery patients[J].Agri,2020,32(2):72-78.
[13]馬晶晶,武淑晶,鄧立琴,等.老年患者髖部骨折手術(shù)麻醉的優(yōu)化策略:髂筋膜間隙阻滯聯(lián)合單側(cè)腰麻[J].中華麻醉學(xué)雜志,2020,40(9):1109-1112.
[14]黃景峰,李敏捷,吳海玲.腰硬聯(lián)合麻醉對(duì)老年高血壓行髖關(guān)節(jié)置換術(shù)患者血管彈性及應(yīng)激反應(yīng)的影響[J].中國老年學(xué)雜志,2021,41(12):2539-2542.
[15]魯美靜,張愷辰,趙金霞,等.腕踝針聯(lián)合靜脈自控鎮(zhèn)痛對(duì)髖關(guān)節(jié)置換術(shù)后疼痛程度、炎性疼痛介質(zhì)及應(yīng)激激素表達(dá)的影響研究[J].中華中醫(yī)藥學(xué)刊,2021,39(10):104-107.
[16]戴漣生,葉俊星,楊志剛,等.髖關(guān)節(jié)置換術(shù)后感染對(duì)血液流變學(xué)、ApoE及皮質(zhì)醇的影響[J].中國老年學(xué)雜志,2019,39(20):5005-5009.
[17]王娟,王濤.蛛網(wǎng)膜下隙與硬脊膜外聯(lián)合阻滯麻醉對(duì)老年髖關(guān)節(jié)置換術(shù)患者圍手術(shù)期認(rèn)知功能及免疫狀態(tài)的影響[J].中國現(xiàn)代醫(yī)學(xué)雜志,2022,32(11):26-31.
[18]陳杰,李莎,李千一,等.艾司氯胺酮聯(lián)合右美托咪定在老年慢性阻塞性肺疾病患者髖關(guān)節(jié)置換術(shù)中的應(yīng)用效果研究[J].實(shí)用心腦肺血管病雜志,2023,31(5):116-120.
[19] LI H,WU T T,TANG L,et al.Association of global DNA hypomethylation with postoperative cognitive dysfunction in elderly patients undergoing hip surgery[J].Acta Anaesthesiol Scand,2019,64(3):354-360.
[20]牛莉,張愛云,閆芳,等.輕比重腰麻對(duì)老年髖關(guān)節(jié)置換術(shù)患者應(yīng)激指標(biāo)和術(shù)后認(rèn)知功能的影響[J].中國煤炭工業(yè)醫(yī)學(xué)雜志,2021,24(3):250-254.
[21]王冬梅,邊長榮.不同麻醉方式對(duì)老年髖關(guān)節(jié)置換手術(shù)患者術(shù)后轉(zhuǎn)歸的影響觀察[J].貴州醫(yī)藥,2020,44(8):1245-1246.
(收稿日期:2024-06-04) (本文編輯:田婧)